Cravath’s London Office Moves to 100 Cheapside

Mylan Inc.’s Senior Notes Offering

May 23, 2018

Cravath represented Mylan Inc. in connection with its €500 million Reg. S senior notes offering. Mylan Inc. is a wholly owned subsidiary of Mylan N.V., a leading global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The transaction closed on May 23, 2018.

The Cravath team included associates Alex M. Dzioba, Justin B. Stein and Jeffrey M. Amico on securities matters, and associate Kiran Sheffrin on tax matters.

Related Practices & Industries

Deals & Cases

April 29, 2024

Mylan’s Appellate Win Affirming Summary Judgment in Securities Class Action

On Monday, April 15, 2024, the U.S. Court of Appeals for the Second Circuit affirmed the U.S. District Court for the Southern District of New York’s granting of summary judgment in favor of Cravath client Mylan in a securities class action related to Mylan’s marketing, pricing and classification of EpiPen as well as alleged conduct concerning generic drug price fixing and market allocation.

Cravath Bicentennial

Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.

Explore

Mylan Inc.’s Senior Notes Offering

Related Practices & Industries

Related News & Insights

Mylan’s Appellate Win Affirming Summary Judgment in Securities Class Action

Cravath Bicentennial